Upanovimab - Sinocelltech
Alternative Names: anti-COVID-19 monoclonal antibody - Sinocelltech; Anti-SARS-CoV-2 monoclonal antibody - Sinocelltech; SCTA-01Latest Information Update: 28 Aug 2023
At a glance
- Originator Sinocelltech
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in China (Parenteral)
- 27 Jan 2022 Sinocelltech withdraws a phase I/II trial for COVID-2019 infections (Combination therapy) in January 2022 (NCT05156645)
- 14 Dec 2021 Sinocelltech plans a phase I/II/III trial for COVID-2019 infections (Combination therapy) in January 2022 (NCT05156645)